Debiovision’s Sanvar Will Be Tough Sell To Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has declared any positive results from a study of vapreotide to be statistically insignificant, immeasurably biased and possibly due to the endoscopic therapy rather than the drug.
You may also be interested in...
Did A Special Protocol Assessment Actually Hurt Debiovision’s Sanvar?
FDA’s Gastrointestinal Drugs Advisory Committee concludes that flaws in the trial designed with FDA made it impossible to determine the efficacy of the drug for acute bleeding resulting from portal hypertension.
Did A Special Protocol Assessment Actually Hurt Debiovision’s Sanvar?
FDA’s Gastrointestinal Drugs Advisory Committee concludes that flaws in the trial designed with FDA made it impossible to determine the efficacy of the drug for acute bleeding resulting from portal hypertension.
GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May
FDA has been digesting both applications for a considerable amount of time.